

Rheumatoid Arthritis

Stuart Weisman, MD
Boulder Medical Center, P.C.
303-622-3724

Introduction

- What is rheumatoid arthritis?
- How is it different than “arthritis”?
- What are the symptoms?
- How is it diagnosed?
- Options for treatment?

Rheumatoid Arthritis

Chronic, systemic inflammatory disease that primarily affects the joints

Arthritis vs Rheumatoid Arthritis

Arthritis

- Associated with aging, injury, obesity
- Affects middle aged to older people
- Symptoms worse with use
 - Very common
 - Often involves weight bearing joints such as back, neck, knees, hips

Rheumatoid Arthritis

- Autoimmune
- Affects young, middle aged and older people
- Symptoms typically worst in the morning or after inactivity
 - 0.5% to 1% of the population
- Predominately small joint involvement

Rheumatoid Arthritis

Estimate - 1.5 million people in U.S.¹

Peak incidence between 50 and 75 years old

Lifetime risk 3.6% for women, 1.7% for men²

Rheumatoid Arthritis

Female to male ratio of 2-3:1

Occurs among all races, ethnicities

Etiology

Cause remains unknown

Abnormal immune response which leads to chronic inflammation in the joints



Etiology

Genetics

Environmental

Hormonal

Genetics

Twins and siblings of RA patients have greater risk for RA^{4,5}

Parents or siblings with RA increase risk of development of RA⁶

HLADR4, PTPN22 genes

Environmental

Cigarette Smoking^{7,8,9}

Obesity⁸

Infection –bacterial and viral^{10,11,12,13,14}

Microbiome¹⁵

Silica¹⁶

Hormones

Women > men

Often improves during pregnancy

Clinical Features

Joint pain and swelling

Fatigue

Morning Stiffness

Clinical Features

Rheumatoid nodules

Pleuritis / pericarditis

Episcleritis / scleritis

Interstitial lung disease

Coronary artery
disease

Episcleritis

Clinical Features

Secondary Sjogren's
syndrome

Felty's syndrome

Vasculitis


Clinical Features

Hands - MCP, PIP
joints

Wrists, shoulders >
elbows


Feet - MTP joints, PIP
joints

Ankles, Knees



Clinical Features

- Jaw (TMJ)
- Neck
- Sternoclavicular, acromioclavicular
- DIP joints (hands)
- Hips



Clinical Features

- Variability in disease
- Classic pattern - symmetrical, multiple joints
- Single or few joints
- Fluctuating symptoms or consistent symptoms

Diagnosis

History, physical exam, and labs

X-rays can help confirm

ACR / EULAR has published diagnostic criteria for RA¹⁷

RA if score of 6 or greater

<i>Joint involvement (0-5)</i>	
1 med/large joint	0
2-10 med/large joints	1
1-3 small joints	2
4-10 small joints	3
>10 joints (at least 2 small)	5
<i>Serology (0-3)</i>	
Neither RF nor ACPA positive	0
At least one test low positive titre	2
At least one test high positive titre	3
<i>Duration of Synovitis (0-1)</i>	
< 6 weeks	0
≥ 6 weeks	1
<i>Acute phase reactants (0-1)</i>	
Neither CRP nor ESR abnormal	0
Abnormal CRP or abnormal ESR	1
<small>http://rheumator.com</small>	

Differential Diagnosis

Infections - Parvovirus, hepatitis B, hepatitis C, HIV, rubella, lyme, post streptococcal arthritis, gonococcal arthritis

Other autoimmune diseases - lupus, Sjogren's syndrome, psoriatic arthritis, reactive arthritis, IBD related arthritis, vasculitis, sarcoidosis, PMR, and others

Crystal induced diseases - gout , pseudogout

Osteoarthritis

Lab Testing

Rheumatoid factor

Anti CCP antibody


Anemia

Elevated ESR / CRP

X-rays

Joint space narrowing

Erosions



MRI

Occasionally used in
rheumatoid arthritis

Most helpful in early
diagnosis

Ultrasound

Ultrasound can be
used to show
inflammation in the
synovium or erosions
in the bone

Prognosis

Individual variability

Elevated ESR and CRP

Elevated RF and anti CCP

X-ray evidence of erosions

Greater number of swollen and tender
joints

Treatment

Why should you treat?

Relief of pain and
fatigue

Restore quality of life

Prevent joint damage
and disability

Prevent early coronary
artery disease^{18,19}

Non Pharmacologic Treatment

Diet

Exercise

Supplements

Acupuncture



Diet

Limited scientific data available^{20,21,22,23,24,25}

Consider foods higher in omega fatty acids - flaxseed oil, walnuts, tofu, shrimp, kale, turnips, spinach, squash



Diet

Arthritis Foundation – Excellent resource for dietary recommendations

<http://www.arthritis.org/living-with-arthritis/arthritis-diet/anti-inflammatory/rheumatoid-arthritis-diet.php>

Exercise

Resistance exercises can be helpful²⁶

Cardiovascular aerobic exercise programs can also be helpful^{27,28}

Aquatic exercises, cycling, weights, walking

Supplements



Fish Oil / Flax²⁹

GLA (Omega 6 fatty acid)³⁰



Supplements

Turmeric
(Curcumin)^{31,32,33}

Boswellia³⁴

www.arthritis.org

Acupuncture

Results from studies have been conflicting^{35,36}

May be helpful

Pharmacologic Treatments

Analgesics

Nonsteroidal anti-inflammatories

Glucocorticoids

Non biologic DMARDs

Biologic DMARDs

Analgesics

acetaminophen /
Tylenol

tramadol / Ultram

opioids (hydrocodone,
oxycodone, morphine,
etc...)

Marijuana
(cannabinoids)³⁷

NSAIDs

ibuprofen

meloxicam

naproxen

indomethacin

diclofenac

piroxicam

etodolac

nabumetone

sulindac

ketoprofen

oxaprozin

celecoxib

Glucocorticoids

Prednisone /
methylprednisolone

Very helpful in
relieving pain and
inflammation

Extensive side effects

Short term use and
low doses if possible



Edward Calvin
Kendall
(1886 - 1972)

Tadeus Reichstein
(1897 - 1996)

Philip Showalter
Hench
(1896 - 1965)

Non Biologic DMARDs

hydroxychloroquine / Plaquenil

doxycycline

sulfasalazine / Azulfidine

minocycline / Minocin

methotrexate / Rheumatrex

cyclosporine / Neoral

leflunomide / Arava

azathioprine / Imuran

gold / Auranofin

Non Biologic DMARDs

Table 1. Oral DMARDs most commonly used to treat RA

Agent	Efficacy	Potential adverse effects	Advantages	Disadvantages	Use in pregnancy	Monitoring requirements
Methotrexate	Very effective at delaying radiographic progression of RA, the efficacy standard by which all other DMARDs are measured	GI complaints (eg, dyspepsia, nausea, anorexia, stomatitis), asymptomatic elevations in liver enzyme levels (risk of liver damage is low), myelosuppression, pulmonary toxicity	Favourable efficacy and toxicity profiles, low cost, weekly dosing regimen, established track record	Potential for hepatic, pulmonary, and haematological toxicity; need to abstain from alcohol during treatment, anxiety about taking a 'chemotherapy' drug	Contraindicated (class X); methotrexate is teratogenic and abortifacient	Measure liver enzyme and creatinine levels, and determine complete blood cell count every 4-8 weeks
Sulfasalazine	Almost as effective as methotrexate at delaying clinical and radiographic progression of RA	Nausea, vomiting, dyspepsia, anorexia, headache, rash, haematological disturbances (GI effects are reduced by use of enteric-coated formulation)	Long-term efficacy only slightly inferior to methotrexate, good side-effect profile	Twice-daily dosing	Generally safe (class B), although sulfasalazine may cause hematuria if used near term	Determine complete blood cell count every 2-4 weeks for first 3 months
Hydroxychloroquine	Has not been proved to delay radiographic progression of RA, but early use does significantly reduce signs and symptoms of disease	Rash, abdominal cramps and diarrhea (all infrequent); severe adverse retinal effects (extremely rare)	Extremely safe and well-tolerated; does not require laboratory monitoring	Patients' concern about potential effect on vision	Category C	Baseline ophthalmological examination and other yearly examinations thereafter for all (ACT) or yearly examinations for high-risk patients (AAS)
Leflunomide	Comparable to that of methotrexate and sulfasalazine	Diarrhea, alopecia, elevated liver enzyme levels (although diarrhea usually responds to symptomatic treatment and alopecia is usually transient)	Efficacy is comparable to that of methotrexate; active metabolite can be removed with cholestyramine in case of pregnancy or severe toxicity	Various possible adverse effects, lack of long-term clinical experience	Contraindicated (class X) known teratogen	Measure liver enzyme and creatinine levels, and determine complete blood cell count every 4-8 weeks

DMARD = disease-modifying antirheumatic drug; RA = rheumatoid arthritis; GI = gastrointestinal; ACE = American College of Rheumatology; AAS = American Academy of Ophthalmology

Long history of use

Most are taken orally

Less expensive than biologic DMARDs

Risks are clearly known

Antibiotics

Doxycycline and minocycline³⁸⁻⁴⁰


Most common side effects: skin, gastrointestinal

Antibiotics

Clarithromycin⁴¹

Roxithromycin⁴²

Levofloxacin⁴³






Biologic DMARDs

Advances in molecular biology led to the development of these medications

Targeted therapy

Main targets presently including anti TNF, anti IL6, B cells, T-cell costimulation, JAK inhibition

Targets in RA



Biologic DMARDs

Etanercept / Enbrel (1998)

Infliximab / Remicade (1998)

Anakinra / Kineret (2001)

Adalimumab / Humira (2003)

Abatacept / Orencia (2006)

Rituximab / Rituxam (2006)

Golimumab / Simponi or Simponi Aria (2009)

Certolizumab / Cimzia (2009)

Tocilizumab / Actemra (2010)

Sarilumab / Kevzara (2017)

Advantages

Very effective at relieving symptoms

Improve quality of life

Prevent joint damage

Minimal side effects

Disadvantages

Cost

Administered by injection or intravenously

Rare, but potentially serious adverse effects

Tofacitinib / Xeljanz

Approved in 2012

JAK inhibitor

Tablet

Taken 1-2 x / day



Sarilumab / Kevzara

FDA approval May 2017

IL6 receptor antagonist

Used as monotherapy or in conjunction with DMARDs

More effective than adalimumab as monotherapy

Biosimilars

Highly similar molecules to branded products

Same clinical effect, safety, route of administration, dosing

Potential for cost savings

For further info: pfizerbiosimilars.com

infliximab – dyyb / Inflectra

Infliximab – abda / Renflexis

etanercept – szzs / Erelzi

adalimumab – atto / Amjevita

Biosimilars

Cost

Insurance

Patient financial support

Interchangeability



RA Med Resources

www.webmd.com/rheumatoid-arthritis/guide/rheumatoid-arthritis-medications

www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/treatment.php

www.uptodate.com (search for rheumatoid arthritis treatments)

www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-treatment

Medications

Severity of the disease

Time to onset of action

Concurrent medical illnesses

Safety

Patient or physician preference

Cost / insurance coverage

Combination Therapy?

Combination therapy has been shown to be more effective than monotherapy⁴⁴⁻⁴⁹

Popular combinations are hydroxychloroquine, sulfasalazine, and methotrexate or anti TNF therapy with methotrexate

Duration of Therapy

Depends on the clinical course⁵⁰

10% - long clinical remission

15 to 30% intermittent symptoms

chronic progressive disease

Future Therapies

Baricitinib, filgotinib,
ABT-494

Sirukumab,
Clazakizumab

More biosimilars

Mavrillilumab

CF101



Conclusion

RA is a common
disease

History, physical
exam, labs, and x-rays
lead to the diagnosis

Non pharmacologic
and pharmacologic
options exist for
treatment

Final Thoughts!

Traditionally
rheumatoid arthritis
has been a
progressively disabling
disease, but
treatments today
relieve symptoms,
restore quality of life,
and prevent the
damage that
previously led to
disability